Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Eltrombopag Clonmel 50 mg film-coated tablets
Medicines register · Ireland

Eltrombopag Clonmel 50 mg film-coated tablets

Authorisation PA0126/377/002 · Clonmel Healthcare Ltd

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Clonmel Healthcare Ltd (all products →)
Active substance
Eltrombopag olamine
Clinical trials
12 clinical trials →
Dosage form
Film-coated tablet
Route of administration
Oral use
ATC code
B02BX05
First authorised
21/02/2025
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Eltrombopag olamine: supply and approvals

29 authorised products on the HPRA list contain Eltrombopag olamine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 19 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 19 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 1 year (since 21 February 2025). The HPRA list marks it as marketed in Ireland.

Other medicines with Eltrombopag olamine in Ireland

25 other products on the HPRA list contain Eltrombopag olamine, from 8 licence holders; 3 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Eltrombopag Clonmel 25 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Eltrombopag Teva 25 mg Film-coated TabletsTEVA GmbHNational authorisation (PA)Marketed
Eltrombopag Teva 50 mg Film-coated TabletsTEVA GmbHNational authorisation (PA)Marketed
Eltrombopag Accord 12.5 mg film-coated tabletsAccord Healthcare S.L.U.Centralised EU authorisationNot stated
Eltrombopag Accord 25 mg film-coated tabletsAccord Healthcare S.L.U.Centralised EU authorisationNot stated
Eltrombopag Accord 50 mg film-coated tabletsAccord Healthcare S.L.U.Centralised EU authorisationNot stated
Eltrombopag Accord 75 mg film-coated tabletsAccord Healthcare S.L.U.Centralised EU authorisationNot stated
Eltrombopag Clonmel 75 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Not marketed
Eltrombopag MSN 25 mg film-coated tabletsMSN Labs Europe LimitedNational authorisation (PA)Not marketed
Eltrombopag MSN 50 mg film-coated tabletsMSN Labs Europe LimitedNational authorisation (PA)Not marketed
Eltrombopag Rowex 12.5 mg film-coated tabletsRowex Limited,National authorisation (PA)Not marketed
Eltrombopag Rowex 25 mg film-coated tabletsRowex Limited,National authorisation (PA)Not marketed

All 26 products with Eltrombopag olamine →

The licence holder

Clonmel Healthcare Ltd holds 429 products on the HPRA list, with 174 different active substances; 325 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.